Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Caliway, Cardiol, Diamyd, Healthbio, Ionis, Mesoblast.
Researchers from Mercer University have presented a middle cerebral artery/ferric chloride (MCA/FeCl3) thromboembolic mouse model of COVID-19-induced stroke and cerebrovascular complications.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Avicanna, Biogen, Calcimedica, Candel, Crispr, Edgewise, Krystal, Lineage, Lykos, Rocket, Trawsfynydd.
Clinical updates, including trial initiations, enrollment status and data readouts and publications: 4DMT, AN2, Anixa, Cervomed, Connecta, Gritstone, Larimar, Mediwound, Nuvalent, Nuvig, Polypid, Shionogi.
Trawsfynydd Therapeutics Inc. has received approval to initiate a first-in-man phase I trial of the novel best-in-class COVID-19 treatment, TRX-01, an inhibitor targeting the SARS-CoV-2 viral main protease (3CL, Mpro).
COVID-19 severity remains open to several questions. Researchers at the University of California Los Angeles (UCLA) have revealed how SARS-CoV-2 causes acute inflammation instead of the symptoms of a common cold. This effect could be initiated by the peptide fragments of the coronavirus released when the host eliminates the virus, which can form pro-inflammatory complexes that trigger an amplified immune response.
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Alterity, Avencell, Bayer, Bioxcel, Eli Lilly, Geovax, GSK, Irlab, Kancera, Kyowa Kirin, Lipocine, Mink, Sangamo, Sanofi, Thermosome, Ultragenyx, Vertex, Vividion.
Clinical updates, including trial initiations, enrollment status and data readouts and publications: 4DMT, Amgen, CSL, Eyepoint, Iregene, Janssen, Ocuphire, Oragenics, Palatin, Pliant, Profoundbio, Rani, Triumvira.
RSS
